Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Click here for more information

CiteULike is a free service for managing and discovering scholarly references - click here to get started.

Sign In to gain access to subscriptions and/or personal tools.
Journal of Child Neurology
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Levisohn, P. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Levisohn, P. M.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Safety and Tolerability of Topiramate in Children

Paul M. Levisohn, MD

Children's Epilepsy Program, The Children's Hospital. 1056 East 19th Avenue B 155, Denver. CO 80218, levisohn.paul{at}tchden.org

Three double-blind, randomized, placebo-controlled studies of topiramate that include children have been published and prospective but unblinded and retrospective reviews have been reported providing information regarding topiramate's safety and tolerability. These studies indicate that side effects tend to occur early in treatment with topiramate, especially in children receiving polypharmacy. Two classes of adverse events are commonly reported: central nervous system and anorexia/weight loss. Central nervous system effects include somnolence, difficulties with concentration, and behavior changes. Tolerance to these effects seems to develop in most children. When it occurs, weight loss has been noted in the first 12 to 18 months, after which normal weight gain resumes, without long-term impact on growth. As opposed to the experience in adults, aphasia and word-finding difficulties are not commonly seen, and parasthesiae are not reported by children. Renal calculi are rare. Life-threatening idiosyncratic reactions have not been attributed to topiramate. While metabolic acidosis has been reported, no other clinically significant laboratory abnormalities have been associated with the use of topiramate in children. (J Child Neurol 2000;15:S22-S26).

Journal of Child Neurology, Vol. 15, No. 1 suppl, S22-S26 (2000)
DOI: 10.1177/088307380001500105
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 J Child NeurolHome page
S. Grosso, E. Franzoni, P. Iannetti, G. Incorpora, C. Cardinali, I. Toldo, A. Verrotti, F. C. Moscano, V. Lo Faro, L. Mazzone, et al.
Efficacy and Safety of Topiramate in Refractory Epilepsy of Childhood: Long-Term Follow-Up Study
J Child Neurol, November 1, 2005; 20(11): 893 - 897.
[Abstract] [PDF]

Home page
 J Child NeurolHome page
N. Watemberg, H. Goldberg-Stern, B. Ben-Zeev, I. Berger, R. Straussberg, S. Kivity, U. Kramer, N. Brand, and T. Lerman-Sagie
Clinical Experience With Open-Label Topiramate Use in Infants Younger Than 2 Years of Age
J Child Neurol, April 1, 2003; 18(4): 258 - 262.
[Abstract] [PDF]